- Bendamustine
-
-
2026-08-12
- CAS:16506-27-7
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Bendamustine.
-
-
2026-08-12
- CAS:16506-27-7
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Bendamustine
-
- $30.00
-
2026-07-15
- CAS:16506-27-7
- Purity: 99.99%
- Supply Ability: 10g
|
| | Bendamustine Basic information |
| Product Name: | Bendamustine | | Synonyms: | 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid;5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid;Bendamustine;-1-methyl-1H-benzo[d]imidazol-2-yl);4-(5-(Bis(2-chloroethyl);4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;4-(5-(bis(2-chloroethyl)aMino)-1-Methyl-1H-benzo[d]iMidazol-2-yl)butanoic acid;1H-BenziMidazole-2-butanoicacid, 5-[bis(2-chloroethyl)aMino]-1-Methyl- | | CAS: | 16506-27-7 | | MF: | C16H21Cl2N3O2 | | MW: | 358.26 | | EINECS: | | | Product Categories: | | | Mol File: | 16506-27-7.mol |  |
| | Bendamustine Chemical Properties |
| Boiling point | 585.2±50.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | -20°C, protect from light | | solubility | DMSO : 100 mg/mL (279.13 mM; Need ultrasonic) | | pka | 4.50±0.10(Predicted) | | form | Solid | | color | White to off-white | | Henry's Law Constant | 2.5×107 mol/(m3Pa) at 25℃, HSDB (2015) | | InChI | InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23) | | InChIKey | YTKUWDBFDASYHO-UHFFFAOYSA-N | | SMILES | C1(CCCC(O)=O)N(C)C2=CC=C(N(CCCl)CCCl)C=C2N=1 |
| | Bendamustine Usage And Synthesis |
| Uses | Treatment of
hematologic cancer, especially non-Hodgkin’s lymphoma. | | Definition | ChEBI: Bendamustine is a member of benzimidazoles. | | Brand name | Ribomustine (Amcis AG, Switzerland). | | in vivo | Bendamustine (25 mg/kg, i.v.) shows potent inhibition on the growth of tumor cells by 91%, 99% and 95% for DoHH-2, Granta 519 and RAMOS models, respectively. Moreover, the antitumor effect of Bendamustine is enhanced by rituximab in DoHH-2 and RAMOS models, but not in Granta 519 model[3]. | | Enzyme inhibitor | This nitrogen mustard and anticancer drug (FWfree-acid = 358.26 g/mol; CAS 16506-27-7), also known by its code name SDX-105, its trade names Treanda, Treakisym, Ribomustin, and Levact, as well as by its systematic name 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2- yl]butanoic acid, is a relatively nonspecific DNA alkylating agent that causes intra- and inter-strand cross-links. Bendamustine is used in the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, nonHodgkin’s lymphoma, multiple myeloma and lung cancer. Pharmacokinetics: After intravenous infusion, >95% of the drug becomes protein-bound, mainly to albumin; however, only free bendamustine is active. Bendamustine is metabolized by liver cytochrome p450, and elimination (renal) is biphasic, with an initial half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. |
| | Bendamustine Preparation Products And Raw materials |
|